Quality of life (QoL): impact of specific immunotherapy (SIT) on social and physical ability.

摘要

The World Allergy Organization (WAO) task force recommendations for standardization of clinical trials with allergen-specific im-munotherapy for respiratory allergy state that, with respect to quality of life (QoL), focusing on clinical manifestations alone might not reflect the burden of allergic diseases. This stems from evidence indicating that allergy is a systemic disease resulting in non-organ-specific symptoms such as tiredness or lack of concentration (1). Despite this, symptom score and medication score, which do not fully reflect patients' perceptions of how treatment affects the disease burden, are often utilized as the only end-points in clinical trials. While QoL questionnaires for both rhinitis and asthma have been developed and validated in many languages, only a small number of trials examining the effects of specific allergen im-munotherapy have considered QoL in assessing the efficacy of treatment.